NCT02319018View on ClinicalTrials.gov

Alisertib and Combination Chemotherapy in Treating Patients With Gastrointestinal Tumors

PHASE1CompletedINTERVENTIONAL
Enrollment

14

Participants

Timeline

Start Date

August 27, 2015

Primary Completion Date

September 29, 2018

Study Completion Date

September 29, 2018

Conditions
Malignant Digestive System Neoplasm
Interventions
DRUG

Alisertib

Given PO

DRUG

Fluorouracil

Given IV

OTHER

Laboratory Biomarker Analysis

Correlative studies

DRUG

Leucovorin Calcium

Given IV

DRUG

Oxaliplatin

Given IV

Trial Locations (5)

21287

Johns Hopkins University/Sidney Kimmel Cancer Center, Baltimore

37232

Vanderbilt University/Ingram Cancer Center, Nashville

48201

Wayne State University/Karmanos Cancer Institute, Detroit

06510

Smilow Cancer Center/Yale-New Haven Hospital, New Haven

06520

Yale University, New Haven

All Listed Sponsors
lead

National Cancer Institute (NCI)

NIH

NCT02319018 - Alisertib and Combination Chemotherapy in Treating Patients With Gastrointestinal Tumors | Biotech Hunter | Biotech Hunter